Beyond transplantation and GvHD, several other autologous CAR- and TCR-redirected FOXP3+ Treg cell therapies are being developed for various autoimmune diseases, including multiple sclerosis (NCT06566261), SLE and lupus nephritis (175, 176), rheumatoid arthritis (NCT06201416), and hidradenitis suppurativa (NCT06361836). This evidence concerns the gene FOXP3 and multiple sclerosis.